# Howard I. Scher

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/howard-i-scher/

## Facts

| Field | Value |
| --- | --- |
| Citations | 134,326 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 164 |
| i10-index | 627 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5072850546 |
| ORCID iD | https://orcid.org/0000-0002-6791-9324 |
| Works | 1,409 |

## Researcher papers

Showing 12 of 28.

- [Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy](https://scholariq.org/papers/increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy/)
- [Abiraterone and Increased Survival in Metastatic Prostate Cancer](https://scholariq.org/papers/abiraterone-and-increased-survival-in-metastatic-prostate-cancer/)
- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [Integrative Genomic Profiling of Human Prostate Cancer](https://scholariq.org/papers/integrative-genomic-profiling-of-human-prostate-cancer/)
- [Integrative Clinical Genomics of Advanced Prostate Cancer](https://scholariq.org/papers/integrative-clinical-genomics-of-advanced-prostate-cancer/)
- [Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients](https://scholariq.org/papers/mutational-landscape-of-metastatic-cancer-revealed-from-prospective-clinical/)
- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy](https://scholariq.org/papers/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy/)
- [Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial](https://scholariq.org/papers/symptom-monitoring-with-patient-reported-outcomes-during-routine-cancer/)
- [Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment](https://scholariq.org/papers/overall-survival-results-of-a-trial-assessing-patient-reported-outcomes-for/)
- [Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group](https://scholariq.org/papers/design-and-end-points-of-clinical-trials-for-patients-with-progressive-prostate/)
- [Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer](https://scholariq.org/papers/inherited-dna-repair-gene-mutations-in-men-with-metastatic-prostate-cancer/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.